Small Cell Lung Cancer Clinical Trials

A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2452 clinical trials
A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

This study is a randomized, national multicenter clinical study which is designed to compare the efficacy of the safety and efficacy of treatment every 3 weeks or 6 weeks in (Non-small-cell-cell cancer, NSCLC) subjects without systematic treatment who used Pembrolizumab after 6 cycles of combined chemotherapy estimated with stable efficacy …

  • 0 views
  • 05 Aug, 2020
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

Participating in the program may improve knowledge and confidence about follow-up care, communication with cancer care and primary care doctors, and quality of life after cancer treatment in non-small cell lung cancer or colorectal cancer survivors.

stage iii colorectal cancer ajcc v8
stage iiib colorectal cancer ajcc v8
carcinoma
stage ia3 lung cancer ajcc v8
cancer treatment
  • 4 views
  • 16 Feb, 2024
  • 1 location
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

The purpose of this study is to find out if the combination of chemotherapy in combination with the immune therapy drug durvalumab would be efficacious and have an acceptable toxicity profile in patients with advanced non-small cell lung cancer.

carcinoma
endocrine therapy
lymphomatous meningitis
stage iv non-small cell lung cancer
nervous
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.

stereotactic body radiation
carcinoma
lung cancer
stereotactic body radiation therapy
stage ia2 lung cancer ajcc v8
  • 0 views
  • 16 Feb, 2024
  • 22 locations
Osimertinib With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

The goal of part 1 of this trial is to find the highest tolerable dose of alisertib or sapanisertib in combination with osimertinib that can be given to patients with EGFR mutated non-small cell lung cancer. The goal of part 2 of this trial is to learn if the dose …

recurrent nsclc
periodic abstinence
carcinoma
stage iiib lung cancer ajcc v8
measurable disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion score (TPS) of less than 50%.

recurrent nsclc
squamous non-small cell lung carcinoma
lung cancer
metastasis
measurable disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.

pd-l1
lymphoma
lung cancer
measurable disease
drug test
  • 0 views
  • 16 Feb, 2024
  • 39 locations
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying …

platelet count
pd-l1
excisional biopsy
durvalumab injection
lung cancer
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Evaluation of GLR2007 for Advanced Solid Tumors

This study is designed to determine the safety, tolerability, and optimal dosing of GLR2007 in participants with advanced solid tumors that do not respond well to standard clinical therapies.

measurable disease
cancer therapy
contrast-enhanced magnetic resonance imaging
BRAF
recurrent disease
  • 0 views
  • 16 Feb, 2024
  • 4 locations
SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions

Prospective phase I study to evaluate the maximum tolerated dose (MTD) of SBRT for thoracic re-irradiation. Dose limiting toxicity will be pneumonitis G3. The potential advantage of the dose escalation planned in this study is the delivery of an ablative dose to radically treat patients with inoperable local relapse, without …

non-small cell lung cancer
lung cancer
metastasis
tumor recurrence
stereotactic body radiation therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location